Immune‑maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity‑modulated radiation

  • Authors:
    • Yuta Shibamoto
    • Masato Okamoto
    • Masanori Kobayashi
    • Shiho Ayakawa
    • Hiromitsu Iwata
    • Chikao Sugie
    • Yoko Mitsuishi
    • Hidenori Takahashi
  • View Affiliations

  • Published online on: April 26, 2013     https://doi.org/10.3892/mco.2013.108
  • Pages: 649-654
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A dendritic cell (DC)‑based vaccine was combined with intensity‑modulated radiotherapy (IMRT) or other conformal radiotherapy (RT), assuming minimal immunosuppression by such RT modalities. In this study, the outcomes in the first 40 patients are presented. The patients had recurrent, metastatic or locally advanced tumors. Nine had previously undergone full‑course RT. Peripheral blood mononuclear cells obtained by leukapheresis were cultured with granulocyte‑macrophage colony‑stimulating factor, interleukin‑4, OK‑432 and prostaglandin E2 to generate DCs, which were pulsed with autologous tumor lysates or tumor‑specific peptides, such as WT1. IMRT using tomotherapy, stereotactic irradiation or 3‑dimensional conformal RT (3DCRT) was initially administered. The standard dose was 30 and 60 Gy in patients with and without previous RT, respectively. Every other week thereafter, up to a total of 7 times, DC vaccines were injected directly into the tumor (n=15) or administered intradermally when DCs were pulsed with tumor lysates or peptides. The tumor response was evaluated according to the response evaluation criteria in solid tumors (RECIST). RT and DC vaccines were well tolerated and there were no major complications. Three patients were not able to complete the planned DC therapy due to disease progression. For the 31 patients receiving full‑dose RT, the response rate was 61% and for the 9 patients who had previously received RT, the response rate was 55%. In 9 patients, the tumor response outside the RT target volume was evaluable: 22% had a partial response (PR), 33% had stable disease (SD) and 44% had progressive disease (PD). In conclusion, a combination of IMRT (or 3DCRT) and DC vaccine is feasible and requires further investigation.
View References

Related Articles

Journal Cover

July 2013
Volume 1 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Shibamoto, Y., Okamoto, M., Kobayashi, M., Ayakawa, S., Iwata, H., Sugie, C. ... Takahashi, H. (2013). Immune‑maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity‑modulated radiation. Molecular and Clinical Oncology, 1, 649-654. https://doi.org/10.3892/mco.2013.108
MLA
Shibamoto, Y., Okamoto, M., Kobayashi, M., Ayakawa, S., Iwata, H., Sugie, C., Mitsuishi, Y., Takahashi, H."Immune‑maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity‑modulated radiation". Molecular and Clinical Oncology 1.4 (2013): 649-654.
Chicago
Shibamoto, Y., Okamoto, M., Kobayashi, M., Ayakawa, S., Iwata, H., Sugie, C., Mitsuishi, Y., Takahashi, H."Immune‑maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity‑modulated radiation". Molecular and Clinical Oncology 1, no. 4 (2013): 649-654. https://doi.org/10.3892/mco.2013.108